Abstract: |
This disclosure provides a technology for managing elevated cytokine levels and the risk of cytokine storm in viral infection, exemplified by SARS-CoV-2, the virus that causes COVID-19. A special mixture of cannabidiol (CBD), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) is extracted from the flowers and leaves of Cannabis sativa (industrial hemp). The purified oil is packed with a surfactant into small micelles, which considerably increases absorption by the gastrointestinal tract, resulting in higher potency and a more rapid onset of action. Daily treatment of patients infected with SARS-CoV-2 reduces the circulating level of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) by 25 to 50% or more. The level of circulating markers of ongoing inflammation, such as C reactive protein (CRP) and/or erythrocyte sedimentation rate (EST) are also reduced. This lowers the risk that the treated patient will suffer the adverse consequences of a cytokine storm, potentially helping the patient to clear the virus and return to good health. |
Inventor: |
Sorensen, Clint (St. George, UT, US); Montgomery, Melanie (Wickenburg, AZ, US); Smith, Matt (Highland, UT, US) |
Applicant: |
WSMEF, LLC (Highland, UT, US) |
Face Assignee: |
N/A |
Filed: |
2021-07-29 |
Issued: |
2022-02-03 |
Claims: |
18 |
|
US20220031635
|
1. A method of reducing circulating levels of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) in a human subject in need thereof by 25% to 50%, the method comprising:
(4)
(6)
|
|
15. A therapeutic preparation of full spectrum hemp oil formulated for oral consumption by a human patient infected with SARS-CoV-2 (the virus that causes COVID-19),
(2)
(5)
|
|